Compare Incyte Corporation (INCY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NetApp Inc. — how do they compare? Incyte Corporation trades at $120.8 (market cap $24.54B), while NetApp Inc. trades at $201.14 (market cap $38.95B). The key difference: NetApp Inc. is the larger of the two by market cap, and NetApp Inc. pays a 1.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NTAP | |
|---|---|---|
Market Cap | $24.54B | $38.95B |
Sector | Health | Technology |
52-Week High | $129.93 | $198.72 |
52-Week Low | $81.61 | $94.11 |
Enterprise Value | $20.04B | $38.10B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
NetApp (NTAP) trades at $200.96, up 1.13% with strong technical momentum as it approaches resistance near $201. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.43 vs. $2.27 expected) and impressive profitability metrics including 70.74% gross margin and 106.73% ROE. Recent acquisitions of JetStream Software and DataPelago strengthen the company's AI infrastructure capabilities, positioning it for growth in the enterprise data storage market.
Outlook remains positive with Wall Street analysts maintaining a mixed but leaning bullish stance (36.62% Buy ratings). Key opportunities include AI-driven demand for data infrastructure, while risks involve elevated valuation multiples (P/E 31.26) and competitive pressures in the storage sector. The current price sits near analyst consensus target of $170.73, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
